Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Anticancer drug targets expressed in the skin
3. Dual effect on cells of EGF receptor inhibitors
4. Folliculitis
5. Pustules - face
6. Pustules - trunk
7. The observed pathology
8. Effect of radiotherapy co-treatment
9. Xerosis
10. Paronychia (1)
11. Paronychia (2)
12. Paronychia on hands
13. Hair modifications
14. Hair modifications - facial hair
15. More hair modifications
16. Hair modifications - eyelash growth
17. EGFRI skin toxicity
18. Time of appearance of skin modifications
19. Effect of dominant negative mutation of EGFR
20. EGFR expression in the skin
21. Consequences of EGFR inhibition
22. Folliculitis intensity and response to treatment
23. The mechanism responsible for the correlation
24. The effect of inhibition of EGFR
25. Sorafenib associated skin manifestations
26. Sorafenib associated skin manifestations- HFSR
27. Sorafenib skin adverse reactions
28. Sorafenib vs. Sunitinib
29. Yellow-skin
30. Lichenoid genital rash
31. Reversible hair depigmentation
32. Reversible hair depigmentation - example
33. The targeted molecules and skin manifestation
34. Side effects observed with BRAF inhibitors
35. Side effects found in vemurafenib clinical study
36. Another study of vemurafenib side effects
37. Follicular rash: pilaris keratosis
38. Maculopapular rash
39. Effect of ipilimumab on rash incidence & severity
40. Photosensitivity
41. Hair modification and alopecia
42. Hyperkeratosis
43. Radiation hypersensitivity and radiation recall
44. Follicular cystic lesions
45. Verrucous papilloma
46. Multiple eruptive skin papillomas
47. Main characteristics of KA and SCC
48. Cutaneous SCC
49. SCC without HPV
50. SCC with HPV
51. Typical KA
52. P16 staining
53. Melanocyte proliferation
54. Vemurafenib-associated skin manifestations
55. Vemurafenib-associated skin manifestations (2)
56. Sorafenib & Sunitinib vs. Vemurafenib
57. Cardiofaciocutaneous syndrome
58. Activation of MAPK pathway in skin
59. Activation of MAPK pathway in skin - mechanism
60. Adverse effects of MEK inhibitors
61. MEK I: Papulo-pustular rash
62. anti-MEK class effect
63. MEK I: Dry skin
64. MEK I: Paronychia
65. MEK I: Dermohypodermatitis
66. Management
67. Rash management
68. Rash classification
69. First look for severity markers
70. Folliculitis treatment
71. Folliculitis treatment: Algorithm
72. Camouflage make-up
73. HFSR management
74. Paronychia management
75. Other management measures
76. Conclusions

Topics Covered

• Clinical presentation of skin adverse events occurring during anti-EGFR, anti-MEK and anti-BRAF agents
• Mechanisms underlying skin manifestation of targeted anticancer agents
• Management of the patients presenting with skin adverse events due to targeted anticancer agents

Links

Categories:

• Cancer
• Clinical Practice
• Pharmaceutical Sciences

Therapeutic Areas:

• Dermatology
• Oncology

Talk Citation

Robert, C. (2013, June 12). Skin side effects targeted anti-EGFR and anti-BRAF therapies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 23, 2024, from https://doi.org/10.69645/LMEC2094.
Export Citation (RIS)

Publication History

• Published on June 12, 2013

Financial Disclosures

• Prof. Caroline Robert has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.